ARMD.MultS: Data of the Age-Related Macular Degeneration Study with...

In Surrogate: Evaluation of Surrogate Endpoints in Clinical Trials

Data of the Age-Related Macular Degeneration Study with multiple candidate surrogates

Description

These are the data of a clinical trial involving patients suffering from age-related macular degeneration (ARMD), a condition that involves a progressive loss of vision. A total of 181 patients participated in the trial. Patients' visual acuity was assessed using standardized vision charts. There were two treatment conditions (placebo and interferon-\alpha). The potential surrogate endpoints are the changes in the visual acuity at 4, 12, and 24 weeks after starting treatment. The true endpoint is the change in the visual acuity at 52 weeks.

Usage

data(ARMD.MultS)

Format

A data.frame with 181 observations on 6 variables.

Id

The Patient ID.

Diff4

The change in the visual acuity at 4 weeks after starting treatment. This endpoint is a potential surrogate for Diff52.

Diff12

The change in the visual acuity at 12 weeks after starting treatment. This endpoint is a potential surrogate for Diff52.

Diff24

The change in the visual acuity at 24 weeks after starting treatment. This endpoint is a potential surrogate for Diff52.

Diff52

The change in the visual acuity at 52 weeks after starting treatment. This outcome serves as the true endpoint.

Treat

The treatment indicator, coded as -1 = placebo and 1 = interferon-\alpha.

Surrogate documentation built on June 8, 2025, 1:09 p.m.